Year: 2025

HCWC expanding revenue streams while strengthening infrastructure and customer engagement  HOLLYWOOD, FL, March 12, 2025 (GLOBE NEWSWIRE) — Healthy Choice Wellness Corp. (“HCWC” or the “Company”) (NYSEAM: HCWC), a holding company operating 19 natural and organic grocery stores across six states, provides a shareholder update highlighting its key growth drivers for 2025, which include operational efficiencies, new revenue streams, investment in key leadership roles and enhanced customer engagement. Healthy Choice Wellness Chairman and CEO Jeff Holman commented, “We are making strategic investments that position HCWC for sustainable growth. By fortifying our team, expanding revenue generation, and enhancing customer engagement, we continue to build a solid foundation for profitability. These initiatives not only drive financial growth...

Biotricity’s latest patents focus on a multi-biometric device platform that functions as both a patch and watch, advancing biometric monitoring solutions for remote patient care. REDWOOD CITY, Calif., March 12, 2025 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB:BTCY), (“Biotricity” or the “Company”), a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce the expansion of its intellectual property (IP) portfolio with 14 new patents. This brings the company’s total to 15 issued patents, with an additional 14 patents pending. The expansion of the company’s IP portfolio underscores Biotricity’s commitment to advancing and improving the patient journey. By streamlining diagnostic processes, Biotricity helps...

MINNEAPOLIS, MN, March 12, 2025 (GLOBE NEWSWIRE) — FOXO Technologies Inc. (NYSE American: FOXO) (the “Company or FOXO”), provides an update on Myrtle Recovery Centers, Inc., (“Myrtle”) and its behavioral health facility in Oneida, Tennessee, and confirms participation in a major alcohol and drug addiction conference in East Tennessee. Myrtle is pleased to announce that its Oneida, Tennessee substance abuse treatment facility has reached stabilization by maintaining an occupancy rate of 75% or greater since the beginning of 2025. In addition, on occasion, the facility has been at capacity unable to accept additional patients over the same period. Myrtle has also, since the beginning of 2025, finalized a number of in-network contracts with major managed care organizations. Myrtle is also pleased to announce its participation as a...

VANCOUVER, British Columbia, March 12, 2025 (GLOBE NEWSWIRE) — Foremost Clean Energy Ltd. (NASDAQ: FMST) (CSE: FAT) (“Foremost” or the “Company”) is pleased to announce its plans for a $6.5 million exploration program in 2025 (the “Program”) across its portfolio of uranium properties in the Athabasca Basin region in northern Saskatchewan. The Program includes the recently announced follow-up drill program on the Hatchet Lake Uranium Property (“Hatchet”) as well as planned exploration on the Murphy Lake South, GR, Blackwing, Wolverine, and CLK properties. Following an initial evaluation of the exploration potential of the 10 properties under option from Denison Mines Corp. (“Denison”)(TSX: DML, NYSE: DNN), Foremost identified several exploration priorities for 2025. The extensive Program will include drilling, geophysical surveys,...

Oral presentations will highlight the implementation of a validated research-use plasma pTau217 assay in the participant screening process for the Phase 2 ALTITUDE-AD study of sabirnetug NEWTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced upcoming scientific presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) in Vienna, Austria from April 1-5, 2025, and the American Academy of Neurology (AAN) Annual Meeting in San Diego, Calif., from April 5-9, 2025. Oral presentations will focus on implementation of a validated research-use plasma...

Rebrands and Introduces New Corporate Identity ATLANTA, March 12, 2025 (GLOBE NEWSWIRE) — Acuity Brands, Inc.’s (NYSE: AYI) corporate name is changing from Acuity Brands, Inc. to Acuity Inc. effective March 26, 2025. Acuity will continue to operate through two business segments, Acuity Brands Lighting (ABL) and Acuity Intelligent Spaces (AIS), formerly Intelligent Spaces Group (ISG). We will continue trading on the New York Stock Exchange under the ticker symbol “AYI”. “Acuity is positioned for long term growth. We are innovators, disruptors and builders who are creating stakeholder value and compounding shareholder wealth,” said Neil Ashe, Chief Executive Officer. “We are using technology to solve problems, redefine industries and create impactful experiences that shape how people live, work and connect.” At Acuity, being an innovator...

MORRISVILLE, N.C., March 12, 2025 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its full year 2024 financial results on Wednesday, March 19, 2025. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The live webcast will be available on Liquidia’s website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidia CorporationLiquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus...

Trial for this rare genetic disease to be conducted by NIH/NIAID in partnership with Corvus ITK inhibition intended to address dysregulation of T cells that causes ALPS and has been shown to be effective at treating the disease in preclinical models BURLINGAME, Calif., March 12, 2025 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has initiated a Phase 2 clinical trial of soquelitinib for the treatment of patients with autoimmune lymphoproliferative syndrome (ALPS), a rare genetic disease. The lead investigator of the trial is V. Koneti Rao, MD, FRCPA, Senior Research Physician, Primary Immune Deficiency Clinic (ALPS Clinic) at NIH Clinical...